Detalles de la búsqueda
1.
NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Future Oncol;
19(25): 1715-1727, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37650734
2.
Association of chemotherapy and comorbidities with overall survival in elderly patients with early breast cancer: a French population-based propensity score-matched analysis.
Int J Clin Oncol;
28(3): 371-381, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36645534
3.
Onco-nephrology: Physicians' Expectations About a New Subspecialty.
J Cancer Educ;
38(3): 878-884, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35840858
4.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat;
191(1): 191-207, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687411
5.
Is Nutritional Screening of Patients with Lung Cancer Optimal? An Expert Opinion Survey of French Physicians and Surgeons.
Nutr Cancer;
71(6): 971-980, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31070050
6.
Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Clin Cancer Res;
2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38819408
7.
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments.
Cancers (Basel);
15(6)2023 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36980624
8.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Eur J Cancer;
191: 112966, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37542936
9.
Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.
Biomedicines;
11(1)2022 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36672591
10.
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes.
Cancers (Basel);
13(10)2021 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34068892
11.
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Cancers (Basel);
14(1)2021 Dec 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008262
12.
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Eur J Cancer;
132: 61-70, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32334337
13.
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Biomark Med;
: 1-3, 2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38884128
14.
Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.
Eur J Cancer;
120: 40-46, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31479946
15.
Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer.
Expert Rev Respir Med;
18(1-2): 5-7, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38488035
16.
Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Eur J Cancer;
121: 192-201, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590080
17.
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation]. / Nouvelles AMMs au niveau européen : alpélisib cancer du sein RH+/HER2− métastatique avec mutation PIK3CA.
Bull Cancer;
107(10): 959-960, 2020 Oct.
Artículo
en Francés
| MEDLINE | ID: mdl-32977934
Resultados
1 -
17
de 17
1
Próxima >
>>